Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonists such as semaglutide are not recommended during pregnancy, but they do not cause permanent infertility. Most women regain normal menstrual cycles and fertility within four to six weeks of stopping treatment, though individual timelines vary based on weight loss progress, metabolic recovery, and underlying hormonal factors.

How GLP-1 Medications Affect Ovulation and Fertility

Semaglutide and other GLP-1 agonists work by slowing stomach emptying and activating appetite-control centers in the brain. These mechanisms do not directly damage ovaries, fallopian tubes, or reproductive organs. However, rapid weight loss—a primary effect of GLP-1 therapy—can temporarily suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH), the hormones that trigger ovulation.

Research shows that weight-loss-induced amenorrhea (missing periods) reverses quickly once the rate of weight loss stabilizes or slows. Women using semaglutide for weight management typically see menstrual function return within four to eight weeks of stopping the medication, even if they maintain their lower weight. This recovery reflects the body's metabolic adjustment rather than permanent reproductive damage.

Stopping Semaglutide Before Pregnancy: Timeline and Planning

If you are planning to become pregnant, your healthcare provider will recommend stopping semaglutide at least two to four weeks before attempting conception. This window allows your body to clear the medication and restart normal ovulation cycles. Unlike some oral medications that linger in the system for months, semaglutide is metabolized within days, so hormone-driven fertility restoration happens relatively quickly.

During the transition period, maintaining stable eating patterns and moderate exercise helps support metabolic recovery. Some women experience increased appetite after stopping GLP-1 therapy, which can affect weight gain during this pre-conception phase. Working with a healthcare team that understands both weight management and reproductive health ensures your transition is medically supervised and psychologically supported.

Pregnancy Outcomes in Women Who Previously Used GLP-1 Therapy

Clinical evidence from GLP-1 users who became pregnant after stopping treatment shows no increased rates of birth defects, miscarriage, or developmental problems. In fact, moderate weight loss before pregnancy—achieved through GLP-1 therapy and sustained after discontinuation—is associated with improved pregnancy outcomes, including lower gestational diabetes risk and reduced pregnancy complications. The key is that GLP-1 drugs are not present during fetal development.

Women with obesity who lose weight through semaglutide and maintain that loss before conception experience better glucose control, lower inflammatory markers, and reduced preeclampsia risk. These metabolic improvements often translate into healthier pregnancies compared to women who conceive while living with untreated obesity. Post-pregnancy weight management after delivery remains a challenge, but prior GLP-1 experience gives women familiarity with the medication if they choose to resume it after breastfeeding ends.

Personalized Weight Management Before and After Pregnancy

PlexusDx offers compounded semaglutide injections starting at $149 per month, with no insurance requirement or membership fees. Women planning pregnancy can work with PlexusDx providers to establish a timeline for stopping therapy, consolidate weight loss achievements, and prepare their body for conception. The Precision Peptide Genetic Test—a $99 add-on after the first treatment month—identifies how your body metabolizes GLP-1 compounds based on genetic variants in appetite and glucose pathways, helping optimize your pre-pregnancy weight loss strategy.

After pregnancy and breastfeeding, many women choose to resume weight management therapy to prevent postpartum weight regain. PlexusDx serves all 50 states with HSA/FSA-eligible pricing, making personalized GLP-1 therapy accessible whenever you are ready to restart treatment. Your healthcare provider can coordinate your pregnancy planning, monitor your fertility recovery, and plan your next phase of weight management—all without gaps in medical oversight.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I get pregnant while taking semaglutide?

Semaglutide is not recommended during pregnancy because its safety in human pregnancy has not been established through clinical trials. If you are trying to conceive or discover you are pregnant, inform your provider immediately so they can advise you on discontinuation.

How long does it take to ovulate again after stopping semaglutide?

Ovulation typically resumes within four to six weeks of stopping semaglutide, even in women who have lost significant weight. Recovery is faster than many people expect because GLP-1 medications themselves do not damage reproductive tissue—they work through appetite and glucose pathways.

Will my periods return to normal after stopping semaglutide?

Yes, menstrual cycles almost always return to their pre-treatment pattern within one to two months of discontinuing semaglutide. If your periods were irregular before starting therapy, they may remain irregular unless underlying hormonal conditions (such as polycystic ovary syndrome) are separately treated.

Is it safer to lose weight before getting pregnant with semaglutide?

Yes—moderate weight loss before pregnancy, achieved through semaglutide and maintained after stopping, reduces gestational diabetes risk, pregnancy complications, and delivery problems.

Can I resume semaglutide after pregnancy and breastfeeding?

Yes, you can restart semaglutide after breastfeeding ends—typically several months postpartum. Many women choose to resume therapy to prevent postpartum weight regain.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves